Pulmonary function in patients surviving to COVID-19 pneumonia

Alessia Fumagalli,Clementina Misuraca,Achille Bianchi,Noemi Borsa,Simone Limonta,Sveva Maggiolini,Daniela Rita Bonardi,Andrea Corsonello,Mirko Di Rosa,Luca Soraci,Fabrizia Lattanzio,Daniele Colombo
DOI: https://doi.org/10.1007/s15010-020-01474-9
2020-07-28
Infection
Abstract:<span class="a-plus-plus abstract-section id-a-sec100"><h3 class="a-plus-plus">Purpose</h3><p class="a-plus-plus">The aim of our study was to assess respiratory function at the time of clinical recovery and 6 weeks after discharge in patients surviving to COVID-19 pneumonia.</p></span><span class="a-plus-plus abstract-section id-a-sec1000"><h3 class="a-plus-plus">Methods</h3><p class="a-plus-plus">Our case series consisted of 13 patients with COVID-19 pneumonia.</p></span><span class="a-plus-plus abstract-section id-a-sec101"><h3 class="a-plus-plus">Results</h3><p class="a-plus-plus">At the time of clinical recovery, FEV1 (2.07 ± 0.72 L) and FVC (2.25 ± 0.86 L) were lower compared to lower limit of normality (LLN) values (2.56 ± 0.53 L, <em class="a-plus-plus">p</em> = 0.004, and 3.31 ± 0.65 L, <em class="a-plus-plus">p</em> &lt; 0.001, respectively), while FEV1/FVC (0.94 ± 0.07) was higher compared to upper limit of normality (ULN) values (0.89 ± 0.01, <em class="a-plus-plus">p</em> = 0.029). After 6 weeks pulmonary function improved but FVC was still lower than ULN (2.87 ± 0.81, <em class="a-plus-plus">p</em> = 0.014).</p></span><span class="a-plus-plus abstract-section id-a-sec102"><h3 class="a-plus-plus">Conclusion</h3><p class="a-plus-plus">These findings suggest that COVID-19 pneumonia may result in clinically relevant alterations in pulmonary function tests, with a mainly restrictive pattern.</p></span>
infectious diseases
What problem does this paper attempt to address?